Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:45 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
APX005M in Patients With Recurrent Ovarian Cancer
NCT05201001 · Nordic Society of Gynaecological Oncology - Clinical Trials Unit · PHASE2 · withdrawn · last registry update 2023-09-11 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “IMP provider company (Apexigen) is sold, thus both IMP and grant is terminated” | – | Registry record, Nordic Society of Gynaecological Oncology - Clinical Trials Unit |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CD40 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2024-07-18Results posted on the registry: Novartis Pharmaceuticals, CFZ533 + Placebo (NCT03610516)
- 2024-07-03Results posted on the registry: Novartis Pharmaceuticals, CFZ533 + Tacrolimus - MMF - corticosteroids (NCT03781414)
- 2024-06-06Results posted on the registry: Novartis Pharmaceuticals, VAY736 + VAY736 Placebo (NCT03656562)
- 2024-05-02Results posted on the registry: Apexigen America, Inc., APX005M + Paclitaxel (NCT03165994)
- 2024-04-10Also stopped (terminated): HiberCell, Inc., odetiglucan + CDX-1140 (NCT05484011)
- 2024-02-28Also stopped (terminated): Albert Einstein College of Medicine, FLT3 Ligand (CDX-301) + anti-CD40 antibody (CDX-1140) (NCT04491084)
- 2024-02-13Also stopped (terminated): Apexigen America, Inc., sotigalimab (NCT04337931)
- 2023-12-22Results posted on the registry: Apexigen America, Inc., sotigalimab (NCT04337931)
- 2023-12-05Results posted on the registry: Apexigen America, Inc., APX005M + Nivolumab (NCT03123783)
- 2023-11-07Results posted on the registry: Hoffmann-La Roche, Regorafenib + Atezolizumab (NCT03555149)
- 2023-11-07Also stopped (terminated): Hoffmann-La Roche, Regorafenib + Atezolizumab (NCT03555149)
- 2023-08-18Results posted on the registry: Yale University, APX005M + Cabiralizumab (NCT03502330)
- 2023-07-17Results posted on the registry: Albert Einstein College of Medicine, FLT3 Ligand (CDX-301) + anti-CD40 antibody (CDX-1140) (NCT04491084)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision